Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926

Douglas M. Dahl, Joseph P. Rodgers, William U. Shipley, M. Dror Michaelson, Chin Lee Wu, William Parker, Ashesh B. Jani, Fabio L. Cury, Richard S. Hudes, Jeff M. Michalski, Alan C. Hartford, Daniel Song, Deborah E. Citrin, Theodore G. Karrison, Howard M. Sandler, Felix Y. Feng, Jason A. Efstathiou

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

PURPOSE To investigate the use of radiation with radiosensitizing chemotherapy following repeated transurethral resection (trimodality therapy) as an alternative to radical cystectomy in T1 bladder cancer which has failed Bacillus Calmette-Guerin (BCG).PATIENTS AND Patients with recurrent T1 bladders who had failed BCG and were recommended METHODS to undergo cystectomy were treated with trimodality therapy.The primary end point was 3-year freedom from cystectomy.Secondary end points were distant metastasis at 3 and 5 years, local recurrence, disease-specific and overall survival (OS), and safety.RESULTS This single-arm phase II study enrolled 37 patients.Efficacy and safety were evaluated in 34 patients after three exclusions.The median follow-up was 5.1 years.The 3-year freedom from cystectomy rate was 88% (lower one-sided 97.5% confidence limit [CI], 72%), meeting the primary study goal.OS at 3 and 5 years was 69% (95% CI, 54 to 85) and 56% (95% CI, 39 to 74), respectively.The distant metastasis rates at 3 and 5 years were 12% (95% CI, 4 to 26) and 19% (95% CI, 7 to 34), respectively.Eight patients died due to urothelial cancer, 12 exhibited local recurrence at 3 years (cumulative incidence: 32%; 95% CI, 17 to 48), 18 experienced grade 3 adverse events, mostly hematological, and one developed grade 4 neutropenia.CONCLUSION Trimodality therapy is an effective potential alternative to radical cystectomy for recurrent high-grade T1 urothelial cancer of the bladder.At 3 years, 88% of the patients remained free of cystectomy.

Original languageEnglish
Pages (from-to)4095-4102
Number of pages8
JournalJournal of Clinical Oncology
Volume42
Issue number34
DOIs
StatePublished - Dec 1 2024

Fingerprint

Dive into the research topics of 'Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926'. Together they form a unique fingerprint.

Cite this